TITLE

CYTOPIA BEGINS SECOND PHASE II STUDY IN BRAIN CANCER

PUB. DATE
October 2008
SOURCE
Worldwide Biotech;Oct2008, Vol. 20 Issue 10, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the commencement of enrolment for Melbourne, Victoria-based Cytopia Limited's Phase Ib/II study of CYT997, the company's novel vascular-disrupting antineoplastic agent. The drug is aimed at patients with an aggressive form of brain cancer known as glioblastoma multiforme (GBM).
ACCESSION #
34517492

 

Related Articles

  • Antiangiogenic Strategies for Treatment of Malignant Gliomas Chi, Andrew S.; Norden, Andrew D.; Wen, Patrick Y. // Neurotherapeutics;Jul2009, Vol. 6 Issue 3, p513 

    Summary: Numerous antiangiogenic agents with diverse mechanisms of action are currently under investigation for the treatment of patients with glioblastoma (GBM), a diagnosis that continues to carry a poor prognosis despite maximal conventional therapy. Early clinical trials suggest that...

  • Brain tumor program offers new options for patients. Abrahams, John M. // Fairfield County Business Journal;2/6/2012, Vol. 48 Issue 6, p18 

    The article reports on the offer of brain tumor program to patients in Connecticut. It cites that 17,000 Americans are diagnosed with glioblastoma multiforme (GBM) which is a deadly form of brain cancer. It mentions that two national clinical trials have shown promising results which provide...

  • RTOG 0525: Examining the Effects of Dose Intensification on Survival.  // Hem/Onc Today;7/10/2012 Supplement, p5 

    The article discusses a study which determined whether dose-intensifying the postradiation temozolomide component of a chemoradiation regime improved overall survival (OS) of patients with glioblastoma.

  • Taking on a Monster. Egan, Mary Ellen // Forbes Global;11/15/2004, Vol. 7 Issue 20, p64 

    Offers a look on two prospective drugs for brain cancer, IL-13 and Transmid, that are giving patients a new lease on life as of 20014. Background on the case of David Herbert, a former pilot diagnosed with glioblastoma multiforme; Makers of IL-13 and Transmid; Number of U.S. citizens diagnosed...

  • Inhibition of Elongation Factor-2 Kinase Augments the Antitumor Activity of Temozolomide against Glioma. Liu, Xiao-yuan; Zhang, Li; Wu, JianPing; Zhou, Lei; Ren, Yi-Jie; Yang, Wei-Qiong; Ming, Zi-Jun; Chen, Bo; Wang, Jianrong; Zhang, Yi; Yang, Jin-Ming // PLoS ONE;Nov2013, Vol. 8 Issue 11, p1 

    Background:Glioblastoma multiforme (GBM), the most common form of brain cancer with an average survival of less than 12 months, is a highly aggressive and fatal disease characterized by survival of glioma cells following initial treatment, invasion through the brain parenchyma and destruction of...

  • Design of New Oxazaphosphorine Anticancer Drugs. Jun Liang; Min Huang; Wei Duan; Xue-Qing Yu; Shufeng Zhou // Current Pharmaceutical Design;Mar2007, Vol. 13 Issue 9, p963 

    The oxazaphosphorines including cyclophosphamide (CPA, Cytoxan, or Neosar), ifosfamide (IFO, Ifex) and trofosfamide (Ixoten) represent an important group of therapeutic agents due to their substantial antitumor and immunomodulating activity. However, several intrinsic limitations have been...

  • Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Robins, H. Ian; Won, M.; Seiferheld, Wendy F.; Schultz, Christopher J.; Choucair, Ali K.; Brachman, David G.; Demas, William F.; Mehta, Minesh P. // Neuro-Oncology;Jan2006, Vol. 8 Issue 1, p47 

    Preclinical studies support the concept that inhibition of protein kinase C (PKC) by tamoxifen (TAM) should provide both antineoplastic effects and radiosensitization. High-dose TAM (80 mg/m² p.o. daily in divided doses) was given with and after conventional radiotherapy (XRT) to inhibit...

  • NeoPharm reaches agreement with FDA on phase III "Precise" trial.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p20 

    Reports that NeoPharm Inc. reached an agreement with the Food and Drug Administration regarding its Precise trial designed to be a study of the company's experimental tumor-targeting, anticancer drug IL13-PE38QQR, that is being investigated as a treatment for first recurrence of glioblastoma...

  • Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Zucchetti, Massimo; Bonezzi, Katiuscia; Frapolli, Roberta; Sala, Federica; Borsotti, Patrizia; Zangarini, Monique; Cvitkovic, Esteban; Noel, Kay; Ubezio, Paolo; Giavazzi, Raffaella; D'Incalci, Maurizio; Taraboletti, Giulia // Cancer Chemotherapy & Pharmacology;Oct2013, Vol. 72 Issue 4, p879 

    Purpose: OTX008 is a galectin-1-targeting compound, currently undergoing a phase I clinical trial. This study aimed at investigating OTX008 pharmacokinetics (PK) and antineoplastic activity. Methods: Pharmacokinetics and activity of OTX008 were analyzed in the human ovarian carcinoma A2780-1A9...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics